Memory Impairment Study (Mild Cognitive Impairment Study)
Status:
Completed
Trial end date:
2004-01-01
Target enrollment:
Participant gender:
Summary
The National Institute on Aging (NIA) is launching a nationwide treatment study targeting
individuals with mild cognitive impairment (MCI), a condition characterized by a memory
deficit, but not dementia. An NIA-funded study recently confirmed that MCI is different from
both dementia and normal age-related changes in memory. Accurate and early evaluation and
treatment of MCI individuals might prevent further cognitive decline, including development
of Alzheimer's disease (AD).
The Memory Impairment Study is the first such AD prevention clinical trial carried out by
NIH, and will be conducted at 65-80 medical research institutions located in the United
States and Canada. This study will test the usefulness of two drugs to slow or stop the
conversion from MCI to AD. The trial will evaluate placebo, vitamin E, and donepezil, an
investigational agent approved by the Food and Drug Administration for another use. Vitamin E
(alpha-tocopherol) is thought to have antioxidant properties, and was shown in a 1997 study
to delay important dementia milestones, such as patients' institutionalization or progression
to severe dementia, by about seven months.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute on Aging (NIA)
Collaborator:
Alzheimer's Disease Cooperative Study (ADCS)
Treatments:
alpha-Tocopherol Donepezil Tocopherols Tocotrienols Vitamin E Vitamins